Novelty in the target landscape of the pharmaceutical industry

Nature Reviews Drug Discovery

Volumn 12, Issue 8, 2013, Pages 575-576

  Agarwal, Pankaj ^a   Sanseau, Philippe ^b   Cardon, Lon R ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE 1; BUNGAROTOXIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR 5; HISTAMINE RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN 1; TAU PROTEIN;

ARTICLE; COMPETITION; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; GEOGRAPHY; HEALTH CARE ACCESS; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING;

CLINICAL TRIALS AS TOPIC; DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; ECONOMIC COMPETITION; MOLECULAR TARGETED THERAPY;

EID: 84881306443     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4089     Document Type: Article

References (2)

1. DiMasi, J. A. & Faden, L. B. Competitiveness in follow on drug R&D: A race or imitation? Nature Rev. Drug Discov. 10, 23-27 (2011).
2. Agrawal, V. & Jamwal, S. Top ten global pharma. World Pharmaceutical Frontiers [online], http://www.worldpharmaceuticals.net/editorials/21/ Top%20ten%20global%20pharma.pdf (2011).